By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) 

25 Science Park
Room 561
New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-5606 Fax: 203-624-5627


SEARCH JOBS



Segment
Drug Discovery





Company News
Melinta Appoints Dr. Eugene Sun As Chief Executive Officer 4/19/2016 8:02:22 AM
Melinta Appoints John Temperato President And Chief Operating Officer 2/23/2016 8:04:57 AM
Melinta Presents Complete Delafloxacin Results From Phase III Study In Patients With Acute Bacterial Skin And Skin Structure Infections At ID Week 10/12/2015 7:09:07 AM
Melinta Banks $67 Million for Skin Infection Antibiotic 6/10/2015 6:50:45 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Joins White House Forum On Antibiotic Stewardship In Commitment To Take Steps To Avert Potential Crisis 6/2/2015 11:05:32 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Study Demonstrates Significant Burden Of Obesity On Patients' Recovery From Acute Bacterial Skin Infections 5/20/2015 8:10:56 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Shows That Health-Related Quality-Of-Life Is Higher In ABSSSI Patients Deemed Cured Vs Improved After End Of Treatment 4/10/2015 8:21:12 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Locks In $30 Million 2/9/2015 7:29:20 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) And Eurofarma Laboratorios Enter Into Commercialization And Distribution Agreements For Delafloxacin In Brazil 1/8/2015 1:26:28 PM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.)'s Lead Candidate Delafloxacin Yields Positive Top-Line Results In Phase 3 Study In Patients With ABSSSI 1/8/2015 7:24:24 AM
123456789
//-->